Homologous Recombination Repair (HRR) is a fundamental pathway for fixing DNA double-strand breaks. When key HRR genes like BRCA1, BRCA2, and others develop mutations, it results in Homologous Recombination Deficiency (HRD), characterized by distinctive "genomic scars." HRD is strongly linked to the development of various human cancers, occurring in approximately 13% of malignant tumors, and is particularly prevalent in ovarian, breast, prostate, and pancreatic cancers. Due to its significant role in predicting sample response in studies involving PARP inhibitors and platinum-based chemotherapy, HRD status is recognized in numerous international and national clinical guidelines as a critical biomarker, offering substantial value for guiding cancer treatment decisions.
Impairment in DNA damage repair (DDR) genes is a recognized factor in the development of several cancers, notably breast, ovarian, prostate, and pancreatic malignancies. Evaluating the status of DDR pathways, particularly by extending biomarker analysis beyond BRCA1/2 to encompass the broader HRR pathway, holds significant investigating targeted therapies in research.
HRD arises from disruptions in the HRR pathway, which can stem from various causes such as gene mutations, promoter methylation, or unidentified factors. Tumors exhibiting HRD are characterized by an inability to effectively repair DNA damage, leading to genomic instability. While directly assessing each potential cause of HRD has limitations, evaluating the downstream consequence of genomic instability provides a means to determine HRD status regardless of the specific underlying mechanism. This assessment can thus focus on either the "cause" (e.g., detecting mutations in HRR genes like BRCA1/2) or the "effect" (identifying genomic scars exceeding a defined threshold or using functional assays).
Our HRR/HRD detection product analyzes tumor HRD status, a critical genomic feature linked to tumor biology across cancer types. HRD positivity serves as a key biomarker for potential PARP inhibitor response in research, with scientific clinical evidence continuously expanding its biological relevance. Beyond this application, Comprehensive HRR pathway profiling identifies additional actionable mutations and gene signatures vital for research sample stratification.
Maximize HRR biomarker coverage with the HRR Panel. This solution targets 39 genes from the pivotal study, delivering a streamlined workflow, robust sensitivity, and low sample input requirements. Customize panels with your genes of interest and add to ready-to-use panel.
Explore Our Ovarian/Pancreas/Prostate/Breast Cancer Panel:
| Cat. No. | Product Name | Brief Description | Inquiry | Basket |
|---|---|---|---|---|
| PNO008 | CDCap™ HRR+HRD Panel Kit | CDCap™ HRR+HRD Panel Kit: A hybridization capture assay detecting mutations in 39 HRR pathway genes and assessing HRD scores via 37,000 SNPs for LOH, TAI, and LST. Enables precision oncology research applications. | ||
| PNO009 | CDAmp™ BRCA1/2 Panel Kit | CDAmp™ BRCA1/2 Panel Kit: A multiplex PCR-based assay detecting germline/somatic point mutations and indels in BRCA1/2 genes across exons and key ClinVar non-exonic regions. |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×
